Abstract
Opioid abuse is a growing problem and has become a national health crisis over the past decade in the USA. Oral ingestion, snorting, and injection are the most commonly employed routes of abuse for an immediate release product. To circumvent these issues, we have developed an egg-shaped tablet (egglet) using fused deposition modeling (FDM) 3D printing technology. Drug-loaded polymeric filaments (1.5 mm) were prepared using hot melt extrusion (HME) followed by printing into egglets of different sizes and infill densities. Based on printability and crush resistance, polyvinyl alcohol (PVA) was found to be the most suitable polymer for the preparation of abuse deterrent egglets. Further, egglets were evaluated and optimized for mechanical manipulation using household equipment, milling, particle size distribution, solvent extraction, and drug release as per the FDA guidance (November 2017). A multifactorial design was used to optimize egglets for solvent extraction and drug release. Extreme hardness (> 500 N) and very large particle size (> 1 mm) on mechanical manipulation confirmed the snorting deterring property while less than 15% drug extraction in 5 min (% Sext) demonstrated the deterrence for injection abuse. Quality target product profile D85 < 30 min and % Sext < 15 was achieved with egglets of 6 mm diameter, 45% infill density, and 15% w/w drug loading. Dose of drug can be easily customized by varying dimension and infill density without altering the composition. HME coupled with FDM 3D printing could be a promising tool in the preparation of patient-tailored, immediate release abuse deterrent formulation.
Similar content being viewed by others
References
Rahman Z, Yang Y, Korang-Yeboah M, Siddiqui A, Xu X, Ashraf M, et al. Assessing impact of formulation and process variables on in-vitro performance of directly compressed abuse deterrent formulations. Int J Pharm. 2016;502(1–2):138–50.
Maincent J, Zhang F. Recent advances in abuse-deterrent technologies for the delivery of opioids. Int J Pharm. 2016;510(1):57–72.
Rahman Z, Zidan AS, Korang-Yeboah M, Yang Y, Siddiqui A, Shakleya D, et al. Effects of excipients and curing process on the abuse deterrent properties of directly compressed tablets. Int J Pharm. 2017;517(1–2):303–11.
Schaeffer T. Abuse-deterrent formulations, an evolving technology against the abuse and misuse of opioid analgesics. J Med Toxicol. 2012;8(4):400–7.
Nalamachu SR, Shah B. Abuse of immediate-release opioids and current approaches to reduce misuse, abuse, and diversion. Postgrad Med. 2018:1–7.
Xu X, Gupta A, Al-Ghabeish M, Calderon SN, Khan MA. Risk based in vitro performance assessment of extended release abuse deterrent formulations. Int J Pharm. 2016;500(1–2):255–67.
Food U, Administration D. Guidance for industry: abuse-deterrent opioids–evaluation and labeling. Silver Spring: US Department of Health and Human Services; 2015.
Food U, Administration D. Guidance for industry: general principles for evaluating the abuse deterrence of generic solid oral opioid drug products. Silver Spring: US Department of Health and Human Services; 2016.
Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007;23(8):648–60.
Cohen JP, Mendoza M, Roland C. Challenges involved in the development and delivery of abuse-deterrent formulations of opioid analgesics. Clin Ther. 2018;40(2):334–44.
Maddineni S, Battu SK, Morott J, Soumyajit M, Repka MA. Formulation optimization of hot-melt extruded abuse deterrent pellet dosage form utilizing design of experiments. J Pharm Pharmacol. 2014;66(2):309–22.
Pergolizzi JV Jr, Raffa RB, Taylor R Jr, Vacalis S. Abuse-deterrent opioids: an update on current approaches and considerations. Curr Med Res Opin. 2018;34(4):711–23.
Peacock A, Larance B, Bruno R, Pearson SA, Buckley NA, Farrell M, et al. Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting. Addiction. 2018.
Alexander L, Mannion RO, Weingarten B, Fanelli RJ, Stiles GL. Development and impact of prescription opioid abuse deterrent formulation technologies. Drug Alcohol Depend. 2014;138:1–6.
Khan MF, Gharibo C. Abuse deterrent opioids. Tech Reg Anesth Pain Manag. 2010;14(2):99–103.
Marnoor SA. Abuse deterrent opioid formulations: a review. Res J Pharm Dosage Forms Technol. 2016;8(2):135.
Boyce H, Smith D, Byrn S, Saluja B, Qu W, Gurvich VJ, et al. In vitro assessment of nasal insufflation of comminuted drug products designed as abuse deterrent using the vertical diffusion cell. AAPS PharmSciTech. 2018:1–14.
Severtson SG, Ellis MS, Kurtz SP, Rosenblum A, Cicero TJ, Parrino MW, et al. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug Alcohol Depend. 2016;168:219–29.
Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37(4):205–17.
Wening K, Schwier S, Stahlberg HJ, Galia E. Application of hot-melt extrusion technology in immediate-release abuse-deterrent formulations. J Opioid Manag. 2017;13(6):473–84.
Cicero TJ, Ellis MS, Kasper ZA. Relative preferences in the abuse of immediate-release versus extended-release opioids in a sample of treatment-seeking opioid abusers. Pharmacoepidemiol Drug Saf. 2017;26(1):56–62.
Iwanicki JL, Severtson SG, McDaniel H, Rosenblum A, Fong C, Cicero TJ, et al. Abuse and diversion of immediate release opioid analgesics as compared to extended release formulations in the United States. PLoS One. 2016;11(12):e0167499.
Beaumont J, Cassidy TA, Oyedele N, Guenther S, Mickle TC. Characterizing abuse progression of immediate-release hydrocodone combination products. J Drug Issues. 2018:0022042618756691.
Yang Y, Wang H, Li H, Ou Z, Yang G. 3D printed tablets with internal scaffold structure using ethyl cellulose to achieve sustained ibuprofen release. Eur J Pharm Sci. 2018;115:11–8.
Goyanes A, Buanz AB, Hatton GB, Gaisford S, Basit AW. 3D printing of modified-release aminosalicylate (4-ASA and 5-ASA) tablets. Eur J Pharm Biopharm. 2015;89:157–62.
Okwuosa TC, Stefaniak D, Arafat B, Isreb A, Wan K-W, Alhnan MA. A lower temperature FDM 3D printing for the manufacture of patient-specific immediate release tablets. Pharm Res. 2016;33(11):2704–12.
Skowyra J, Pietrzak K, Alhnan MA. Fabrication of extended-release patient-tailored prednisolone tablets via fused deposition modelling (FDM) 3D printing. Eur J Pharm Sci. 2015;68:11–7.
Goole J, Amighi K. 3D printing in pharmaceutics: a new tool for designing customized drug delivery systems. Int J Pharm. 2016;499(1–2):376–94.
Goyanes A, Robles Martinez P, Buanz A, Basit AW, Gaisford S. Effect of geometry on drug release from 3D printed tablets. Int J Pharm. 2015;494(2):657–63.
Martinez PR, Goyanes A, Basit AW, Gaisford S. Influence of geometry on the drug release profiles of stereolithographic (SLA) 3D-printed tablets. AAPS PharmSciTech:1–7.
Administration UFD. Center for drug evaluation and research. Application number: 200534Orig1s000. Clinical pharmacology and biopharmaceutics review (s). 2010.
Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm. 2004;1(1):85–96.
Laboratories R. RIOMET (metformin hydrochloride) [package insert]. Jacksonville: Ranbaxy Laboratories Inc; 2017.
Pharma P. OXYCONTIN® (oxycodone hydrochloride) [package insert]. Stamford: Purdue Pharma L.P.; 2007.
Palekar S, Nukala PK, Mishra SM, Kipping T, Patel K. Application of 3D printing technology and quality by design approach for development of age-appropriate pediatric formulation of baclofen. Int J Pharm. 2018.
Patki M, Patel K. Development of a solid supersaturated self-nanoemulsifying preconcentrate (S-superSNEP) of fenofibrate using dimethylacetamide and a novel co-processed excipient. Drug Dev Ind Pharm. 2018;(just-accepted):1–44.
Lang B, McGinity JW, Williams RO. Hot-melt extrusion – basic principles and pharmaceutical applications. Drug Dev Ind Pharm. 2014;40(9):1133–55.
Hajare AA, Patil VA. Formulation and characterization of metformin hydrochloride floating tablets. Asian J Pharm Res. 2012;2(3):111–7.
Corporation EM. Tech Info Parteck MXP_EN_MSIG 2016 [Available from: http://www.emdmillipore.com/US/en/products/small-molecule-pharmaceuticals/formulation/solid-dosage-form/parteck-excipients/parteck-mxp/Ieyb.qB.lAcAAAFYLEQeWww_,nav. Accessed 11 Jan 2018.
De Jaeghere W, De Beer T, Van Bocxlaer J, Remon JP, Vervaet C. Hot-melt extrusion of polyvinyl alcohol for oral immediate release applications. Int J Pharm. 2015;492(1–2):1–9.
2016. Available from: http://www.emdmillipore.com/US/en/product/Parteck-SI-150-Sorbitol,MDA_CHEM-103583. Accessed 11 Jan 2018.
De Jaeghere W, De Beer T, Van Bocxlaer J, Remon JP, Vervaet C. Hot-melt extrusion of polyvinyl alcohol for oral immediate release applications. Int J Pharm. 2015;492(1):1–9.
Cailly-Dufestel V, Herry C, Bacon J, Oury P, Inventors; Google Patents, assignee. Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion 2010.
Fransén N, Björk E, Nyström C. Development and characterisation of interactive mixtures with a fine-particulate mucoadhesive carrier for nasal drug delivery. Eur J Pharm Biopharm. 2007;67(2):370–6.
Bartholomäus J, Schwier S, Brett M, Stahlberg H, Galia E, Strothmann K. New abuse deterrent formulation (ADF) technology for immediate-release opioids. Drug Dev Deliv. 2013;13(8):76–81.
Food U, Administration D. Center for drug evaluation and research. Application number: 206162Orig1s000. Clinical pharmacology and biopharmaceutics review (s). 2014.
Kumar V, Dixon D, Tewari D, Wadgaonkar DB, inventors; Google Patents, assignee. Extended release opioid abuse deterrent compositions and methods of making same 2012.
Chobisa D, Patel K, Monpara J, Patel M, Vavia P. Development and characterization of an organic solvent free, proliposomal formulation of Busulfan using quality by design approach. Int J Pharm. 2018;535(1–2):360–70.
Mishra SM, Rohera BD. An integrated, quality by design (QbD) approach for design, development and optimization of orally disintegrating tablet formulation of carbamazepine. Pharm Dev Technol. 2017;22(7):889–903.
Saurí J, Millán D, Suñé-Negre J, Colom H, Ticó J, Miñarro M, et al. Quality by design approach to understand the physicochemical phenomena involved in controlled release of captopril SR matrix tablets. Int J Pharm. 2014;477(1–2):431–41.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no competing interests.
Additional information
Guest Editors: Heather Boyce, Steve R. Byrn, and Stephen W. Hoag
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nukala, P.K., Palekar, S., Patki, M. et al. Abuse Deterrent Immediate Release Egg-Shaped Tablet (Egglets) Using 3D Printing Technology: Quality by Design to Optimize Drug Release and Extraction. AAPS PharmSciTech 20, 80 (2019). https://doi.org/10.1208/s12249-019-1298-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1208/s12249-019-1298-y